Literature DB >> 16905600

Chronic hyperglycemia impairs functional vasodilation via increasing thromboxane-receptor-mediated vasoconstriction.

Lusha Xiang1, Jay S Naik, Sean R Abram, Robert L Hester.   

Abstract

Individuals with hyperglycemia exhibit impaired exercise performance and functional vasodilatory response. Based on the importance of arachidonic acid (AA) metabolites in functional vasodilation and the increased thromboxane-to-prostacyclin ratio in diabetes, we hypothesized that chronic hyperglycemia in diabetes increases thromboxane-receptor (TP)-mediated vasoconstriction, resulting in an attenuated functional vasodilation. Three groups of lean Zucker rats (8 wk) were used to test the effects of chronic hyperglycemia on endothelial function: normal, streptozotocin (STZ; 70 mg/kg ip), and STZ + insulin (2 U/day). After 4 wk of treatment, spinotrapezius arcade arterioles were chosen for microcirculatory observation. Arteriolar diameter was measured following muscle stimulation and 10 microM AA application in the absence and presence of 1 microM SQ-29548 (TP antagonist). STZ rats exhibited significantly higher fasting glucose levels and attenuated functional and AA-induced dilation compared with normal animals. SQ-29548 improved the vasodilatory responses in STZ rats but had no effect in controls. Insulin treatment normalized both the glucose levels and the vasodilatory responses, and SQ-29548 treatment had no effect on functional or AA-mediated vasodilation in STZ + insulin animals. These results suggest that the impaired functional vasodilation in diabetic rats is due to hyperglycemia-mediated increases in TP-mediated vasoconstriction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16905600     DOI: 10.1152/ajpheart.00623.2006

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  6 in total

Review 1.  Microvascular perfusion heterogeneity contributes to peripheral vascular disease in metabolic syndrome.

Authors:  Jefferson C Frisbee; Adam G Goodwill; Stephanie J Frisbee; Joshua T Butcher; Fan Wu; Paul D Chantler
Journal:  J Physiol       Date:  2014-12-18       Impact factor: 5.182

Review 2.  Skeletal muscle performance in metabolic disease: Microvascular or mitochondrial limitation or both?

Authors:  Jefferson C Frisbee; Matthew T Lewis; Robert W Wiseman
Journal:  Microcirculation       Date:  2018-12-23       Impact factor: 2.628

3.  Improved functional vasodilation in obese Zucker rats following exercise training.

Authors:  Mohamad Sebai; Silu Lu; Lusha Xiang; Robert L Hester
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-06-17       Impact factor: 4.733

4.  Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome.

Authors:  Adam G Goodwill; Stephanie J Frisbee; Phoebe A Stapleton; Milinda E James; Jefferson C Frisbee
Journal:  Microcirculation       Date:  2009-11       Impact factor: 2.628

5.  Integration of skeletal muscle resistance arteriolar reactivity for perfusion responses in the metabolic syndrome.

Authors:  Jefferson C Frisbee; John M Hollander; Robert W Brock; Han-Gang Yu; Matthew A Boegehold
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-04-22       Impact factor: 3.619

6.  Quantitative evaluation and comparison of coronary artery characteristics by 3D coronary volume reconstruction.

Authors:  Yongcheol Kim; Jonathan James Hyett Bray; Benjamin Waterhouse; Alexander Gall; Georgia May Connolly; Eva Sammut; Vito Domenico Bruno; Robert Tulloh; David Adlam; Thomas W Johnson
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.